Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/32010
Title: Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer
Authors: Almeida, Carlos E. B. de
Alves, Lais Nascimento
Rocha, Henrique F.
Cabral Neto, Januário Bispo
Missailidis, Sotiris
Affilliation: Instituto de Radioproteção e Dosimetria. Comissão Nacional de Energia Nuclear. Laboratório de Radiobiologia. Divisão de Física Médica. Rio de Janeiro, RJ, Brasil.
Instituto de Radioproteção e Dosimetria. Comissão Nacional de Energia Nuclear. Laboratório de Radiobiologia. Divisão de Física Médica. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Instituto de Radioproteção e Dosimetria. Comissão Nacional de Energia Nuclear. Laboratório de Radiobiologia. Divisão de Física Médica. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Biofísica Carlos Chagas Filho. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Abstract: Aptamers are oligonucleotide reagents with high affinity and specificity, which among other therapeutic and diagnostic applications have the capability of acting as delivery agents. Thus, aptamers are capable of carrying small molecules, nanoparticles, radiopharmaceuticals or fluorescent agents as well as nucleic acid therapeutics specifically to their target cells. In most cases, the molecules may possess interesting therapeutic properties, but their lack of specificity for a particular cell type, or ability to internalise in such a cell, hinders their clinical development, or cause unwanted side effects. Thus, chemotherapy or radiotherapy agents, famous for their side effects, can be coupled to aptamers for specific delivery. Equally, siRNA have great therapeutic potential and specificity, but one of their shortcomings remain the delivery and internalisation into cells. Various methodologies have been proposed to date, including aptamers, to resolve this problem. Therapeutic or imaging reagents benefit from the adaptability and ease of chemical manipulation of aptamers, their high affinity for the specific marker of a cell type, and their internalisation ability via cell mediated endocytosis. In this review paper, we explore the potential of the aptamers as delivery agents and offer an update on current status and latest advancements.
Keywords: Aptamers
Cancer
Chemotherapy
siRNA
Radiopharmaceutics
Issue Date: 2017
Citation: ALMEIDA, Carlos E. B. de et al. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer. International Journal Of Pharmaceutics, Amsterdam, v. 525, n. 2, p.334-342, 2017.
DOI: 10.1016/j.ijpharm.2017.03.086
ISSN: 1873-3476
Copyright: open access
Appears in Collections:Biomanguinhos - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
F09-1-s2.0-S0378517317302740-main.pdf1 MBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.